Search clinical trials for: Erlotinib Hydrochloride

Total 7869 results

Northwestern University
OSI Pharmaceuticals

Withdrawn

Erlotinib for Treatment of Psoriasis

Psoriasis

United States
Alaunos Therapeutics

Unknown

Phase I Study of Indibulin in Combination With Erlotinib in Advanced Solid Tumors

Advanced Solid Tumors

United States
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Clinical Trial to Evaluate the Efficacy and Safety of Anotinib Hydrochloride Capsule Combined With Epirubicin Hydrochloride Versus Placebo Combined With Epirubicin Hydrochloride in First-line Treatment of Advanced Soft Tissue Sarcoma

Soft Tissue Sarcoma

China
Andrew B Lassman, MD
Genentech, Inc.; OSI Pharmaceuticals

Completed

EGFR Inhibition Using Weekly Erlotinib for Recurrent Malignant Gliomas

Brain Cancer

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Erlotinib in Treating Patients With Recurrent or Metastatic Skin Squamous Cell Carcinoma

Metastatic Skin Squamous Cell Carcinoma | Recurrent Skin Squamous Cell Carcinoma

United States
Montefiore Medical Center
Genentech, Inc.

Completed

OSI-774 (Erlotinib, Tarceva) in Elderly Patients

Non-Small Cell Lung Cancer

United States
Pasi A. Janne, MD, PhD
Massachusetts General Hospital; Dana-Farber Cancer Institute; Beth Israel Deaconess... and other collaborators

Completed

Erlotinib in Women With Previously Untreated Adenocarcinoma of the Lung

Adenocarcinoma | Non-small Cell Lung Cancer

United States
OSI Pharmaceuticals

Terminated

Single-agent Erlotinib in Patients Previously Treated With Oral Etoposide in Protocol OSI-774-205

Ependymoma

United States, Canada, United Kingdom
Kyowa Kirin Co., Ltd.

Completed

A Study of ARQ 197 in Combination With Erlotinib

Advanced/Recurrent Non-small-cell Lung Cancer

Japan
Hoffmann-La Roche

Completed

A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer

Pancreatic Cancer

Australia, Hong Kong, Romania, Germany, Russian Federation, United Kingdom, Bulgaria, Malaysia, Latvia, Slovenia, Croatia, Brazil, Italy, Lithuania, India, Mexico, Singapore, Peru, Ukraine
Hoffmann-La Roche

Completed

A Study of Tarceva (Erlotinib) in Patients With Locally Advanced, Metastatic or Recurrent Non-Small Cell Cancer Who Present Epidermal Growth Factor Receptor Mutations

Non-Squamous Non-Small Cell Lung Cancer

Bulgaria
Hoffmann-La Roche

Completed

A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Present EGFR Mutations

Non-Small Cell Lung Cancer

Finland
Hoffmann-La Roche

Completed

A Study of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer Naive to Chemotherapy

Non-Small Cell Lung Cancer

Italy, Spain, Netherlands, France, Germany, United Kingdom
Pfizer

Terminated

Trial Of CP-751, 871 And Erlotinib In Refractory Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung | Carcinoma, Squamous Cell | Carcinoma, Large Cell | Carcinoma, Adenosquamous Cell

United States, Bulgaria, Italy, Spain, Ukraine, Belgium, France, Ireland, Korea, Republic of, Poland, Russian Federation, United Kingdom, Hungary, Serbia, Taiwan, Canada, South Africa, Brazil, Romania, Greece, Puerto Rico, Czech Republic and more
Hoffmann-La Roche

Terminated

A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC) Having Received Tarceva Monotherapy.

Non-Small Cell Lung Cancer

United States, Canada, France, Poland
Hellenic Oncology Research Group
University Hospital of Crete

Completed

Erlotinib as 1st Line Treatment in NSCLC Stage IIIB/IV

Non Small Cell Lung Cancer

Greece
AZ-VUB
Hoffmann-La Roche

Unknown

First-Line EGFR-1 Tyrosine Kinase Inhibition in Patients With NSCLC With Mutant EGFR Gene

Lung Neoplasms | Non-Small Cell Lung Cancer | Adenocarcinoma, Bronchiolo-Alveolar

Belgium
New Mexico Cancer Care Alliance

Completed

A Phase 1 Protocol of 5-Azacytidine and Erlotinib in Advanced Solid Tumor Malignancies

Advanced Solid Tumor Malignancies

United States
Zhejiang Cancer Hospital

Unknown

TACE Combined With Anlotinib Treatment of Middle-advanced Hepatocellular Carcinoma (HCC) Patients

Carcinoma, Hepatocellular

China
University of Oklahoma
OSI Pharmaceuticals

Terminated

Trial of Erlotinib in Patients With JAK-2 V617F Positive Polycythemia Vera (OSI-TAR-766)

Polycythemia Vera

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Astellas Pharma US, Inc.

Completed

Erlotinib Prevention of Oral Cancer (EPOC)

Oral Cancer

United States
M.D. Anderson Cancer Center
United States Department of Defense

Completed

BATTLE Program: Erlotinib in Previously Treated Subjects With Advanced NSCLC

Lung Cancer

United States
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI); OSI Pharmaceuticals

Completed

Erlotinib Before and After Surgery in Treating Patients With Muscle-Invasive Bladder Cancer

Bladder Cancer

United States
University of Alabama at Birmingham
OSI Pharmaceuticals

Terminated

7 Day's of Erlotinib Neo-adjuvant, Followed by Adjuvant Erlotinib-gemcitabine in Pancreatic Cancer Patients

Pancreatic Cancer

United States
Hoffmann-La Roche

Completed

A Study of the Efficacy and Safety of MetMAb Combined With Tarceva in Patients With Met-Positive Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer

China
SCRI Development Innovations, LLC
GlaxoSmithKline; OSI Pharmaceuticals

Completed

Randomized, Double-Blind Trial of Erlotinib/Pazopanib or Erlotinib/Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer

Non Small Cell Lung Cancer

United States
Bristol-Myers Squibb

Completed

A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLC

Non Small Cell Lung Cancer

Korea, Republic of, Taiwan, United States, Spain, France, Argentina, Canada, Poland
OSI Pharmaceuticals

Completed

A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors (RADIANT)

Non-small Cell Lung Cancer

United States, Hungary, Spain, Taiwan, Korea, Republic of, Italy, United Kingdom, Canada, Australia, Belgium, Germany, Austria, Poland, Romania, Argentina, France, Czech Republic, Greece, Russian Federation
National Cancer Institute (NCI)

Completed

Erlotinib, Gemcitabine, and Radiation Therapy in Treating Patients With Locally Advanced Unresectable Pancreatic Cancer

Adenocarcinoma of the Pancreas | Recurrent Pancreatic Cancer | Stage III Pancreatic Cancer | Stage II Pancreatic Cancer

United States
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study of TQB2450 Injection and Anlotinib Hydrochloride Capsules to Treat Triple Negative Breast Cancer (TNBC)

Triple Negative Breast Cancer (TNBC)

China
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Terminated

Erlotinib Hydrochloride and Isotretinoin in Treating Patients With Recurrent Malignant Glioma

Adult Anaplastic Astrocytoma | Adult Anaplastic Oligodendroglioma | Adult Diffuse Astrocytoma | Adult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma | Adult Mixed Glioma | Adult Oligodendroglioma | Recurrent Adult Brain Tumor

United States
OSI Pharmaceuticals
National Cancer Institute (NCI)

Completed

Erlotinib Combined With Gemcitabine in Treating Patients With Newly Diagnosed Locally Advanced or Metastatic Pancreatic Cancer or Other Solid Tumors

Pancreatic Cancer | Unspecified Adult Solid Tumor, Protocol Specific

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Erlotinib and Gemcitabine in Treating Patients With Metastatic Breast Cancer Previously Treated With An Anthracycline and/or a Taxane

Breast Cancer

United States
University of California, Davis
National Cancer Institute (NCI); Genentech, Inc.; Aventis Pharmaceuticals

Completed

Docetaxel and Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors

Lung Cancer | Unspecified Adult Solid Tumor, Protocol Specific

United States
Fred Hutchinson Cancer Center

Completed

Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity Cancer

United States
University of Pittsburgh

Completed

Comparison of Biomarker Modulation by Inhibition of EGFR and/or SRC Family

Head and Neck Cancer | Non Small Cell Lung Cancer

United States
Nanfang Hospital of Southern Medical University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study of Sequential Anlotinib Followed by EP Regimen Plus Concurrent Radiotherapy for Unresectable Stage III Non-small Cell Lung Cancer

Unresectable Stage III Non-small Cell Lung Cancer

China
Northwestern University
M.D. Anderson Cancer Center

Completed

Bevacizumab and Erlotinib After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma

Brain and Central Nervous System Tumors

United States
National Cancer Institute (NCI)

Completed

Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors

Recurrent Childhood Medulloblastoma | Recurrent Childhood Ependymoma | Recurrent Neuroblastoma | Recurrent Osteosarcoma | Recurrent Childhood Rhabdomyosarcoma | Previously Treated Childhood Rhabdomyosarcoma | Recurrent Childhood Soft Tissue Sarcoma | Recurrent Childhood Malignant Germ Cell Tumor | Recurrent... and other conditions

United States
Astellas Pharma Global Development, Inc.

Terminated

A Study of ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI)

Non-Small-Cell Lung Cancer

Japan
OSI Pharmaceuticals
Canadian Cancer Trials Group

Completed

OSI-774 (Tarceva) in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Carcinoma, Non-small-cell Lung

Canada, United States, Australia, Singapore, Israel, China, Argentina, Germany, Sweden, Brazil, Chile, Greece, Mexico, New Zealand, Romania, South Africa, Thailand
Hoffmann-La Roche

Completed

A Study to Assess the Incidence of EGFR Mutation in Patients With Newly Diagnosed Locally Advanced or Metastatic Non-Small Cell Lung Cancer in the UK, And of Tarceva (Erlotinib) as First-Line Therapy in EGFR Mutation Positive Patients.

Non-Squamous Non-Small Cell Lung Cancer

United Kingdom
Genentech, Inc.

Completed

A Study to Evaluate Erlotinib in Patients With Advanced or Metastatic Breast Cancer During or Following Chemotherapy

Breast Cancer
Genentech, Inc.

Completed

A Study of the Safety and Efficacy of Tarceva in Patients With First Relapse of Grade IV Glioma (Glioblastoma Multiforme)

Glioblastoma
Agennix

Completed

A Study Comparing Sequential Satraplatin & Erlotinib to Erlotinib in Unresectable Stage 3/4 Non-small-cell Lung Cancer (NSCLC)

Lung Cancer

United States, Canada, Chile
Astellas Pharma Inc
OSI Pharmaceuticals

Completed

Phase I Study of OSI-930 and Erlotinib in Cancer Tumors

Advanced Solid Tumors

United States, United Kingdom
Shanghai Chest Hospital
Guangdong Provincial People's Hospital; Shanghai Pulmonary Hospital, Shanghai...

Temporarily not available

Evaluating Efficacy and Safety of Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Chemotherapy

Non-small Cell Lung Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing...
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Study of AK105 With Anlotinib and Radiotherapy Adjuvant Therapy in MGMT Unmethylated Newly Diagnosed Glioblastoma.

MGMT-Unmethylated Glioblastoma

China
Kadmon Corporation, LLC

Terminated

KD019 Versus Erlotinib in Subjects With Stage IIIB/IV Non Small Cell Lung Cancer With Progression After First- or Second-Line Chemotherapy

Carcinoma, Non-Small-Cell Lung

United States
OSI Pharmaceuticals

Completed

A Pharmacokinetic Study of Erlotinib in Cancer Patients With Advanced Solid Tumors, With Adequate and Moderately Impaired Hepatic Function

Advanced Solid Tumors

United States, United Kingdom

Search clinical trials for: Erlotinib Hydrochloride

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Senegal

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations